Epitope-based peptide vaccine design and target site depiction against Ebola viruses: An immunoinformatics study

Scandinavian Journal of Immunology

Volumn 82, Issue 1, 2015, Pages 25-34

  Khan, M A ^a   Hossain, M U ^b   Rakib Uz Zaman, S M ^c   Morshed, M N ^a  

^a MILITARY INSTITUTE OF SCIENCE AND TECHNOLOGY   (Bangladesh)

^b MAWLANA BHASHANI SCIENCE AND TECHNOLOGY UNIVERSITY   (Bangladesh)

^c SHAHJALAL UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; RNA DIRECTED RNA POLYMERASE; EBOLA VACCINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; PROTEIN BINDING; SUBUNIT VACCINE;

ALLERGENICITY; AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BETA TURN; CELLULAR IMMUNITY; DRUG DESIGN; DRUG TARGETING; EBOLAVIRUS; HLA SYSTEM; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MOLECULAR DOCKING; PRIORITY JOURNAL; T LYMPHOCYTE; BIOLOGY; CHEMISTRY; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; PROTEIN SECONDARY STRUCTURE;

COMPUTATIONAL BIOLOGY; EBOLA VACCINES; EBOLAVIRUS; EPITOPES, T-LYMPHOCYTE; HEMORRHAGIC FEVER, EBOLA; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; VACCINES, SUBUNIT;

EID: 84930976490     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12302     Document Type: Article

References (69)

1. Beer B, Kurth R, Bukreyev A. Characteristics of Filoviridae: Marburg and Ebola viruses. Naturwissenschaften 1999;86:8-17.
2. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849-62.
3. Genton C, Cristescu R, Gatti S et al. Recovery potential of a western lowland gorilla population following a major Ebola outbreak: results from a ten year study. PLoS ONE 2012;7:e37106.
4. Bausch DG, Towner JS, Dowell SF et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007;196 (Suppl. 2):S142-7.
5. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Luttecontre les Epidemies a Kikwit. J Infect Dis 1999;179 (Suppl 1):S87-91.
6. Jaax N, Jahrling P, Geisbert T et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995;346:1669-71.
7. Towner JS, Sealy TK, Khristova ML et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4:e1000212.
8. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. Emergence of Zaire Ebola virus disease in Guinea - preliminary report. N Engl J Med 2014;371:1418-25.
9. Bausch DG, Schwarz L. Outbreak of Ebola virus disease in Guinea: where ecology meets economy. PLoS Negl Trop Dis 2014;8:e3056.
10. ECDC. Outbreak of Ebola virus disease in West Africa. Stockholm: ECDC, 2014.
11. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola Viruses. In: Knipe DM, Howley PM, eds. Fields Virology, Vol. 1. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2007:1409-48.
12. Centers for Disease Control and Prevention. Bioterrorism agents/diseases, 2014. Available at: http://www.bt.cdc.gov/agent/agentlist-category.asp#a (accessed 10th January 2015).
13. Atanas P, Irini D. T-cell epitope vaccine design by immunoinformatics. Open Biol 2013;3:120139.
14. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHCII peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008;9 (Suppl. 12):S22.
15. Arnon R. A novel approach to vaccine design-epitope-based vaccines. FEBS J 2006;273:33-4.
16. Lapelosa M, Gallicchio E, Arnold GF, Arnold E, Levy RM. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol 2009;385:675-91.
17. Chakraborty S, Chakravorty R, Ahmed M et al. A computational approach for identification of epitopes in dengue virus envelope protein: a step towards designing a universal dengue vaccine targeting endemic regions. Silico Biol 2010;10:235-46.
18. Sharmin R, Islam AB. A highly conserved WDYPKCDRA epitope in the RNA directed RNA polymerase of human coronaviruses can be used as epitope-based universal vaccine design. BMC Bioinformatics 2014;15:161.
19. Hasan MA, Khan MA, Datta A, Mazumder MHH, Hossain MU. A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment. Mol Immunol 2015;65:189-204.
20. Hasan MA, Hossain M, Alam MJ. A computational assay to design an epitope-based Peptide vaccine against Saint Louis encephalitis virus. Bioinform Biol Insights 2013;7:347-55.
21. Klavinskis LS, Whitton JL, Oldstone MB. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol 1989;63:4311-6.
22. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007;196 (Suppl. 2):S430-7.
23. Pratt WD, Wang D, Nichols DK et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010;17:572-81.
24. Sullivan NJ, Geisbert TW, Geisbert JB et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006;3:e177.
25. Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424:681-4.
26. Feldmann H, Jones SM, Daddario-DiCaprio KM et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;3:e2.
27. Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11:786-90.
28. Bukreyev A, Rollin PE, Tate MK et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007;81:6379-88.
29. Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Recent advances in Ebolavirus vaccine development. Human Vaccines 2010;6:439-49.
30. Hoenen T, Groseth A, Feldmann H. Current Ebola vaccines. Expert Opin Biol Ther 2012;12:859-72.
31. Fausther-Bovendo H, Mulangu S, Sullivan NJ. Ebolavirus vaccines for humans and apes. Curr Opin Virol 2012;2:324-9.
32. Galvani AP et al. Ebola vaccination: if not now, when? Ann Intern Med 2014;161:749-50.
33. The UniProt Consortium. Activities at the universal protein resource (UniProt). Nucleic Acids Res 2014;42:D191-8.
34. Magrane M, the UniProt consortium. UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011;29:bar009.
35. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007;8:4.
36. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 2007;8:424.
37. Buus S, Lauemoller SL, Worning P, Kesmir C, Frimurer TS et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003;62:378-84.
38. Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005;6:132.
39. Tenzer S, Peters B, Bulik S, Schoor O, Lemmel E et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 2005;62:1025-37.
40. Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 2007;8:361.
41. Liao L, Noble WS. Combining pairwise sequence similarity and support vector machines for detecting remote protein evolutionary and structural relationships. J Comput Biol 2003;10:857-68.
42. Muh HC, Tong JC, Tammi MT. AllerHunter: a SVM-pairwise system for assessment of allergenicity and allergic cross-reactivity in proteins. PLoS ONE 2009;4:e5861.
43. Thevenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P et al. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res 2012;40:W288-93.
44. Trott O, Olson AJ. AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010;31:455-61.
45. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN et al. The protein data bank. Nucleic Acids Res 2000;28:235-42.
46. + T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci USA 2010;107:12599-604.
47. Accelrys Software Inc. Discovery Studio Modeling Environment, Release 4.0. San Diego: Accelrys Software Inc., 2013.
48. Fieser TM, John A, Tainer H. Influence of protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein a-helix. Proc Natl Acad Sci USA 1987;84:8568-72.
49. Karplus PA, Schulz GE. Prediction of chain flexibility in proteins. Naturwissenschaften 1985;72:212-3.
50. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of anti-genic determinants on protein antigens. FEBS Lett 1990;276:172-4.
51. Emini EA, Hughes JV, Perlow DS, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 1985;55:836-9.
52. Parker JM, Guo D, Hodges RS. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 1985;25:5425-32.
53. Andersen PH, Nielsen M, Lund O. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci 2006;15:2558-67.
54. Rini JM, Schulze-Gahmen U, Wilson IA. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 1992;255:959-65.
55. Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 1987;47:45-148.
56. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 1993;2:1511-9.
57. Gill SC, Von HP. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989;182:319-26.
58. Guruprasad K, Reddy BV, Pandit MW. Correlation between stability of a protein and its dipeptide composition, a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng 1990;4:155-61.
59. Ikai A. Thermostability and aliphatic index of globular proteins. J Biochem 1980;88:1895-8.
60. Šali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. Evaluation of comparative protein modelling by MODELLER. Proteins 1995;23:318-26.
61. Söding J, Biegert A, Lupas AN. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res 2005;33:W244-8.
62. Dong X, Zhang Y. Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. Biophys J 2011;101:2525-34.
63. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer, an environment for comparative protein modeling. Electrophoresis 1997;18:2714-23.
64. Ramachandran GN, Ramakrishnan C, Sasisekharan V. Stereochemistry of polypeptide chain configurations. J Mol Biol 1963;7:95-9.
65. Benkert P, Tosatto SC, Schomburg D. QMEAN, A comprehensive scoring function for model quality assessment. Proteins 1998;71:261-77.
66. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y et al. CASTp, computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 2006;34:116-8.
67. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A. In: Walker, John M, (Ed.); Protein Identification and Analysis Tools on the ExPASy Server. New York: The Proteomics Protocols Handbook, 2005:571-607.
68. Geourjon C, Deleage G. SOPMA, significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Comput Appl Biosci 1995;11:681-4.
69. Sarkar A, Kellogg GE. Hydrophobicity - shake flasks, protein folding and drug discovery. Curr Top Med Chem 2010;10:67-83.